From Regulation Magazine:
...no one has yet articulated a sensible, ethical reason for why we should continue to allow thousands of patients to die each year instead of paying surviving families a few thousand dollars to motivate an increased rate of consent for organ removal.
...Certainly, there are parties directly involved in this policy debate that benefit economically from a continuation of the organ shortage. For example, owners of dialysis clinics, investigators who receive funding for xenograph research, the agencies that manage organ procurement and allocation activities, and even the transplant centers themselves all may experience significant financial gains from shortage conditions. As with any cartel-type arrangement, producers receive increased profits when they are able to restrict supply.
